[Long-term outcome of radical prostatectomy in an observation period of at least 10 years].
OBJECTIVE
To evaluate the long-term outcome of radical prostatectomy in unselected patients with prostate cancer of relatively poor prognosis.


METHODS
Between 1977 and 1989, 293 patients underwent radical retropubic prostatectomy. We analyzed 224 patients with a minimum follow-up of 10 years (mean 14 years, range 10.5 to 24 years).


RESULTS
The pathological stage distribution of these 224 patients was pT1 in 14.3 %, pT2 43.6 %, pT3 39.1 % and pT4 3 %. Of these patients, 50 (22.3 %) had positive lymph nodes and 45 (20.1 %) positive margins. At 10 years after surgery, the actuarial survival rate for all patients was 67.1 % and the cancer-specific survival rate 85 %. Once progression of the disease developed, the median actuarial time to death was 5.5 years. Since PSA measurements were not introduced in the follow-up after radical prostatectomy until 1986, PSA data were available in only 84 (37.5 %) patients. In a survival analysis, preoperative PSA (< 10 ng/ml vs. > or = 10 ng/ml) was a significant predictor of the probability of positive margins (22 % vs. 78 %) and cancer-specific survival (87 % vs. 69 %) after 10 years.


CONCLUSIONS
Long-term survival can be expected even in patients with locally advanced prostate cancer treated with radical prostatectomy.
Fischer
C
C
Urologische Klinik, Krankenhaus Hohe Warte, Bayreuth.
Schreiber
A
A
Altwein
J E
JE
D014408:Biomarkers, Tumor / Q000097:blood; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000401:mortality*; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery*
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen